A team of researchers at the University of Pennsylvania has pinpointed a brain immune protein that appears to accelerate Parkinson's disease progression, opening a potential new avenue for early intervention in a condition that affects over a million Americans.
The protein, called glycoprotein nonmetastatic melanoma B (GPNMB), acts like a delivery system for the toxic clumps responsible for Parkinson's damage, allowing them to spread from one brain cell to the next. In laboratory experiments, scientists were able to block this protein using specially designed antibodies, halting the spread of the damaging material.
The research, published in Neuron, comes at a critical moment. Currently, no approved drug can slow or stop Parkinson's progression, even in its earliest stages when symptoms are mild and patients might benefit most from treatment.
"Many patients with Parkinson's disease are diagnosed in the early stages, when symptoms are relatively mild, but there is currently no treatment that slows the progression," said lead researcher Alice Chen-Plotkin, MD, a neurology professor at Penn. "These early results are a promising step towards developing this type of treatment."
Parkinson's develops through a cascade of cellular damage. A protein called alpha-synuclein becomes misshapen, forming abnormal clumps inside neurons. These clumps destroy the affected cell and then migrate into neighboring healthy neurons, where the process repeats. As the damage spreads through the brain, patients develop tremors, walking difficulties, balance problems, and swallowing troubles. Current treatments like levodopa and deep-brain stimulation reduce symptoms but do not address the underlying disease progression.
The Penn team's breakthrough came from tracking where GPNMB originates. Microglia, the brain's resident immune cells, produce the protein in response to neuronal injury and death. When neurons are damaged, microglia ramp up GPNMB production. Enzymes then release GPNMB from the cell surface, allowing it to circulate between brain cells and facilitate the spread of alpha-synuclein clumps.
In lab cultures of neurons, antibodies designed to block GPNMB successfully prevented the pathological alpha-synuclein from moving between cells. This suggests that interrupting the protein could theoretically halt or slow the neurodegenerative cascade.
Chen-Plotkin described the process as a vicious cycle: "Alpha-synuclein accumulates in neurons, damaging the neurons. The injury to the neurons initiates the release of GPNMB, which accelerates the spread of alpha-synuclein, leading to further damage. Interrupting this cycle would hopefully slow, or even stop, the spread of alpha-synuclein through the brain and the neurodegeneration that follows."
To test whether their findings applied to actual human Parkinson's disease, the research team analyzed brain tissue samples from 1,675 individuals stored at the Penn Brain Bank. They discovered that people carrying genetic variants associated with higher GPNMB production showed more extensive alpha-synuclein pathology. This connection provided independent confirmation that GPNMB genuinely influences disease progression in humans.
Notably, elevated GPNMB levels correlated only with Parkinson's pathology, not with damage seen in other neurodegenerative diseases like Alzheimer's, suggesting the protein plays a specific role in this particular condition.
While the results are encouraging, Chen-Plotkin cautioned that the path to human therapy remains long. "These results are promising for laboratory models and human brain tissue analysis, but we still have a lot of work to do before we can translate this therapy into humans. That being said, these results are encouraging as we continue to work towards a novel treatment for PD."
The research was supported by multiple sources, including the National Institutes of Health, SPARK-NS, and the Parker Family Chair in Neurology.
Author Jessica Williams: "If these antibodies hold up in animal models and eventually human trials, they could give neurologists their first real shot at slowing Parkinson's before it devastates a patient's life."
Comments